Alivus Life Sciences logo

Alivus Life Sciences financials and balance sheet

NSE: ALIVUSBSE: 543322Pharmaceuticals & BiotechnologySmall Cap

Formerly Glenmark Life Sciences
Last close ₹1,250.60down ₹18.40 (1.45%)BSE ₹1,247.30

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,269.00.

52-week range of traded prices to 23 Oct 2026
₹819.00Low, 22 Jan 2026₹1,493.80High, 31 Aug 2026
Market cap
₹15,354 Cr502nd largest listed
P/E
25.5
P/B
4.6
Dividend yield
0.40%
ROE
19.6%
ROCE
22.7%
Debt to equity
0.00
Volume, NSE
87,23655.9% delivered

5 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Alivus Life Sciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹2,552 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue2,552
  2. Materials and goods−1,067
  3. Employee costs−272
  4. Other expenses−416
  5. Operating profit797
  6. Depreciation−75
  7. Other income+60
  8. One-off items−26
  9. Finance costs−5.4
  10. Profit before tax751
  11. Tax−187
  12. Net profit564

What the company owns

  • Plant, investments and other assets₹1,435 Cr
  • Receivables₹1,073 Cr
  • Current investments₹780 Cr
  • Inventory₹692 Cr
  • Cash and bank₹2 Cr

What pays for it: net worth and liabilities

  • Net worth₹3,332 Cr
  • Owed to suppliers₹372 Cr
  • Other liabilities₹278 Cr

Profit and loss

Standalone, ₹ crore, years to March.Alivus Life Sciences quarterly results

₹ croreMar 2022Filed 21 AprMar 2023Filed 29 AprMar 2024Filed 26 AprMar 2025Filed 10 JunMar 2026Filed 14 May
Revenue from operations2,1232,1612,2832,3872,552
1,5071,5191,6091,7041,755
Materials and goods bought1,0431,0141,0021,0811,067
Employee costs169180258252272
Other expenses296325349372416
Operating profit before depreciation616642674683797
Operating margin29.0%29.7%29.5%28.6%31.2%
Materials, % of revenue49.1%46.9%43.9%45.3%41.8%
Employee costs, % of revenue7.9%8.3%11.3%10.5%10.7%
Other expenses, % of revenue13.9%15.0%15.3%15.6%16.3%
Depreciation and amortisation3842536175
Operating profit after depreciation578600621622722
Other income1529123560
Finance costs281225
Profit before one-off items and tax565629631654777
One-off items0000−26
Profit before tax565629631654751
146162160169187
Net profit419467471486564
Other comprehensive income00−5−11
Total comprehensive income419467465484566
Net margin19.7%21.6%20.6%20.3%22.1%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2022Filed 21 AprMar 2023Filed 29 AprMar 2024Filed 26 AprMar 2025Filed 10 JunMar 2026Filed 14 May
2,0542,1382,3322,8173,332
Share capital2525252525
Reserves2,0302,1142,3082,7933,308
Borrowings00000
384504439470508
336079124143
Total assets2,4712,7022,8503,4113,983
7068529341,0761,334
1,7651,8501,9162,3352,649
Net debt−512−309−302−549−783
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2022Filed 21 AprMar 2023Filed 29 AprMar 2024Filed 26 AprMar 2025Filed 10 JunMar 2026Filed 14 May
598313414392565
736467576554739
103−194−126−171−137
Receivables−59−13438−205−89
Inventories−3−88−83−39−67
Payables7498−3419−13
Other working capital91−70−475431
Tax paid−138−154−163−163−173
Capital spending132170129166307
Free cash flow465143285225258
−122−154−116−616−570
−79−388−279−6−64
Dividends paid129386276061
Shares bought back00000
Shares issued1,0120010
Net change in cash397−22818−230−69
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Standalone, ₹ per share, years to March.Alivus Life Sciences dividend history

₹ per shareMar 2022Filed 21 AprMar 2023Filed 29 AprMar 2024Filed 26 AprMar 2025Filed 10 JunMar 2026Filed 14 May
Earnings per share₹35.63₹38.11₹38.43₹39.63₹45.99
Diluted earnings per share₹35.63₹38.11₹38.38₹39.52₹45.90
Dividend per share₹21.00₹21.00₹22.50₹5.00₹5.00
Book value per share₹167.66₹174.51₹190.35₹229.92₹271.49
Dividend payout61.4%55.1%58.5%12.6%10.9%
Shareholder yield−15.7%8.0%2.9%0.0%0.5%
Market cap at the year end (₹ crore)5,6224,8149,51613,24811,933

Ratios

Standalone, years to March.Alivus Life Sciences PE ratio and valuation

RatioMar 2022Filed 21 AprMar 2023Filed 29 AprMar 2024Filed 26 AprMar 2025Filed 10 JunMar 2026Filed 14 May
Revenue growth–1.8%5.6%4.5%6.9%
Operating profit growth–4.3%5.0%1.2%16.8%
Net profit growth–11.5%0.8%3.1%16.2%
Earnings per share growth–7.0%0.8%3.1%16.0%
20.4%22.3%21.1%18.9%18.4%
–1.9 pts−1.2 pts−2.2 pts−0.5 pts
From the net margin–1.9 pts−1.0 pts−0.3 pts1.6 pts
From asset turnover–−0.6 pts−0.3 pts−1.5 pts−1.9 pts
From borrowing–0.6 pts0.1 pts−0.4 pts−0.2 pts
Return on capital employed28.1%28.1%26.6%22.1%21.7%
Cash conversion142.7%67.1%87.8%80.6%100.2%
Interest cover20.71,097.3401.5257.7134.4
Debt to equity0.000.000.000.000.00
Receivable days116136122148153
Inventory days181217243228237
Payable days108143134132127
Cash conversion cycle, days189211231244263
Working capital days149175188201194
Asset turnover0.860.840.820.760.69
Assets per rupee of net worth1.201.231.241.221.20
Sales per rupee of plant3.632.792.872.532.51
Capital spending to depreciation3.494.042.412.744.07
Plant being built, % of plant in use15.7%6.4%12.7%10.0%26.9%

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
15.3%
Cash from operations against operating profit
70.9%
Measure5 years3 years
Revenue growth, yearly rate–5.7%
Profit growth, yearly rate–6.5%
Return on equity, average20.2%19.4%
Return on capital employed, average25.3%23.5%
Operating margin, average29.6%29.8%
Net margin, average20.9%21.0%
Asset turnover, average0.790.76
Cash conversion cycle, days, average227246
Interest cover, average382.3264.5
Debt to equity, average0.000.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations2,2811,370565
Cash from investing−1,579−1,302−570
Cash from financing−816−350−64
Capital spending905602307
Dividends paid85233761
Shares bought back000
Shares issued for cash1,01310
Borrowings raised000
Borrowings repaid96100

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––535
Altman Z-scorePublished threshold 1.8111.578.3814.3116.5214.08
Beneish M-scorePublished threshold −1.78–−2.28−2.15−2.14−2.00
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–11.906.2622.6715.40
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––0.980.790.90
Receivables growth less revenue growthOur threshold 0 percentage points–18.00−10.7722.153.73
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–19.7911.52−6.773.99
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–3.112.29−1.67−1.59
Assets under construction, years of additionsOur threshold 2 years of additions–0.211.380.451.81
Effective tax ratePublished threshold 17.16 per cent25.8825.7225.4125.7624.87
Tax charged less tax paid, % of profitOur threshold 10 percentage points1.421.29−0.410.851.81
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
16 Sep 2025India Ratings and Research Private Limited (opens in a new tab)Bank loan facilitiesIND AA; IND A1+Review, OtherStable700
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.